Back to Search
Start Over
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
- Source :
- Lung cancer (Amsterdam, Netherlands). 139
- Publication Year :
- 2019
-
Abstract
- Objectives Low-frequency epidermal growth factor receptor (EGFR) T790M mutation could be detected by ultrasensitive methods in EGFR tyrosine kinase inhibitor (TKI)-naive non-small cell lung cancer (NSCLC). However, the impact of pretreatment T790M (preT790M) on the efficacy of EGFR-TKIs and on resistance remains unclear. Materials and methods Two independent cohorts consisting of advanced EGFR-mutated NSCLC patients treated with first-line EGFR-TKIs, a derivation cohort that started treatment between August 2013 and July 2016 (cohort A, n = 44) and a validation cohort between August 2016 and December 2017 (cohort B, n = 22), were examined in this study. Among these, 28 patients underwent re-biopsy at disease progression. DNAs from pretreatment tumor biopsy samples and re-biopsy samples were assessed to detect T790M by the Cobas EGFR Mutation Test v2 (Cobas) and for quantitating T790M by droplet digital polymerase chain reaction (ddPCR). Results Detection rates of preT790M were 40.9% (18/44) in cohort A and 45.5% (10/22) in cohort B by ddPCR, and none by Cobas. A cutoff value of 0.3% for dividing into high- vs. low-preT790M allele frequency was determined by receiver operating characteristic curve analysis in cohort A. Progression-free survival (PFS) was significantly shorter in the high- preT790M group (n = 12) than in the low-preT790M (n = 6) and negative (n = 26) groups (combined low-preT790M) (median: 6.9 vs. 13.8 months, P = 0.00073). These observations were validated in cohort B [median: 6.2 (n = 5) vs. 15.3 months (n = 17), P = 0.0029]. In 28 paired biopsies, Cobas detected post-progression T790M in 60% (3/5) of the high-preT790M, in 57% (4/7) of the low-preT790M, and in 56% (9/16) of the negative-preT790M groups. Conclusion EGFR-mutated NSCLC with high preT790M had significantly shorter PFS on EGFR-TKIs. However, preT790M abundance may not necessarily confer post-TKI T790M resistance.
- Subjects :
- 0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
Adult
Male
Cancer Research
medicine.medical_specialty
Lung Neoplasms
medicine.disease_cause
03 medical and health sciences
T790M
0302 clinical medicine
Mutation Rate
Internal medicine
Carcinoma, Non-Small-Cell Lung
Medicine
Humans
Digital polymerase chain reaction
Epidermal growth factor receptor
Lung cancer
Allele frequency
Protein Kinase Inhibitors
Aged
Retrospective Studies
Aged, 80 and over
Mutation
biology
Receiver operating characteristic
business.industry
Middle Aged
medicine.disease
Prognosis
respiratory tract diseases
ErbB Receptors
Survival Rate
030104 developmental biology
030220 oncology & carcinogenesis
Cohort
biology.protein
Female
business
Follow-Up Studies
Subjects
Details
- ISSN :
- 18728332
- Volume :
- 139
- Database :
- OpenAIRE
- Journal :
- Lung cancer (Amsterdam, Netherlands)
- Accession number :
- edsair.doi.dedup.....79be99440294b0c71209d938fd46322b